CO6190603A2 - Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide - Google Patents

Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide

Info

Publication number
CO6190603A2
CO6190603A2 CO09079796A CO09079796A CO6190603A2 CO 6190603 A2 CO6190603 A2 CO 6190603A2 CO 09079796 A CO09079796 A CO 09079796A CO 09079796 A CO09079796 A CO 09079796A CO 6190603 A2 CO6190603 A2 CO 6190603A2
Authority
CO
Colombia
Prior art keywords
compound
glucocorticoid receptor
carbomoil
methylpiridin
fenantren
Prior art date
Application number
CO09079796A
Other languages
English (en)
Inventor
Rajesh Venkateswaran Devraj
Xiao Hu
Kevin D Jerome
Mark Gerrd Obukowicz
Ronald Keith Webber
Paul V Rucker
Lisa Olson
Gary A Crescenzo
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO6190603A2 publication Critical patent/CO6190603A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Abstract

1.- Un compuesto de fórmula Ien la que R1 es -P(O)(OH)2; o una sal del mismo. 2.- El compuesto de la reivindicación 1, en el que el compuesto es:o una sal del mismo. 3.- El compuesto de la reivindicación 1, en el que el compuesto es:4.- La sal de calcio del compuesto de la reivindicación 1. 5.- La sal de sodio del compuesto de la reivindicación 1. 6.- Una composición que comprende el compuesto de la reivindicación 1 o sal del mismo y un portador. 7.- Un procedimiento que comprende poner en contacto un receptor de glucocorticoides con el compuesto de la reivindicación 1 o sal del mismo.8.- Un procedimiento de tratamiento de una afección mediada por la actividad de receptor de glucocorticoides en un sujeto, que comprende administrar al sujeto un compuesto de fórmula I:en la que R1 es -P(O)(OH)2;o sal del mismo.
CO09079796A 2007-02-02 2009-07-31 Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide CO6190603A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88798107P 2007-02-02 2007-02-02

Publications (1)

Publication Number Publication Date
CO6190603A2 true CO6190603A2 (es) 2010-08-19

Family

ID=39315208

Family Applications (2)

Application Number Title Priority Date Filing Date
CO09079796A CO6190603A2 (es) 2007-02-02 2009-07-31 Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide
CO09079789A CO6220937A2 (es) 2007-02-02 2009-07-31 Compuestos triciclicos composiciones y procedimientos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CO09079789A CO6220937A2 (es) 2007-02-02 2009-07-31 Compuestos triciclicos composiciones y procedimientos

Country Status (43)

Country Link
US (7) US7547714B2 (es)
EP (1) EP2114970B1 (es)
JP (1) JP4599462B2 (es)
KR (2) KR101107949B1 (es)
CN (2) CN101616925B (es)
AP (1) AP2455A (es)
AR (2) AR065135A1 (es)
AT (1) ATE518872T1 (es)
AU (1) AU2008211613B2 (es)
BR (1) BRPI0808634A2 (es)
CA (1) CA2676670C (es)
CL (2) CL2008000330A1 (es)
CO (2) CO6190603A2 (es)
CR (2) CR10948A (es)
CU (2) CU23824A3 (es)
CY (2) CY1110962T1 (es)
DK (1) DK2114970T3 (es)
DO (1) DOP2009000190A (es)
EA (1) EA016494B1 (es)
EC (2) ECSP099552A (es)
ES (2) ES2368286T3 (es)
GE (2) GEP20125404B (es)
GT (2) GT200900209A (es)
HK (1) HK1135108A1 (es)
HN (2) HN2008000179A (es)
HR (1) HRP20110702T1 (es)
IL (1) IL199972A (es)
MA (2) MA31158B1 (es)
MX (1) MX2009008284A (es)
MY (3) MY153057A (es)
NI (2) NI200900149A (es)
NZ (1) NZ578638A (es)
PE (2) PE20081736A1 (es)
PL (1) PL2114970T3 (es)
PT (2) PT2114970E (es)
RS (2) RS51970B (es)
SI (1) SI2114970T1 (es)
SV (2) SV2009003346A (es)
TN (1) TN2009000324A1 (es)
TW (2) TWI373466B (es)
UA (2) UA94639C2 (es)
WO (1) WO2008093227A1 (es)
ZA (2) ZA200906060B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
CN101616925B (zh) 2007-02-02 2012-05-23 辉瑞产品公司 三环化合物及其作为糖皮质激素受体调节剂的用途
PT2307375E (pt) * 2008-07-28 2015-01-14 Pfizer Compostos da fenantrenona, composições e métodos
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137844A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
CA2798697A1 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
SG187909A1 (en) * 2010-08-27 2013-03-28 Corcept Therapeutics Inc Pyridyl-amine fused azadecalin modulators
MX2013010576A (es) * 2011-03-15 2014-03-12 Abbvie Inc Moduladores de receptores de hormonas nucleares.
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) * 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
WO2014094357A1 (en) 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
DE202015104742U1 (de) 2014-05-16 2015-10-08 Liqwd, Inc. Keratinbehandlungsformulierungen und Verwendungen derselben
JP6873906B2 (ja) 2014-10-20 2021-05-19 オイスター ポイント ファーマ インコーポレイテッド 眼の病状の治療方法
CN104591988A (zh) * 2014-12-29 2015-05-06 甘肃省化工研究院 6-溴-2-萘满酮的合成方法
CN113350353A (zh) 2015-03-23 2021-09-07 墨尔本大学 呼吸性疾病的治疗
EP3970724A1 (en) 2016-04-07 2022-03-23 Oyster Point Pharma, Inc. Methods of treating ocular conditions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) * 1986-06-19 1988-08-26 Pechiney Aluminium Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
WO2000066522A1 (en) * 1999-04-30 2000-11-09 Pfizer Products Inc. Glucocorticoid receptor modulators
WO2001005229A1 (en) 1999-07-15 2001-01-25 The General Hospital Corporation Non-defective epstein-barr viral vector
IL180679A0 (en) * 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
ATE327974T1 (de) 2000-10-28 2006-06-15 Pfizer Prod Inc Modulatoren des glucocorticoid-rezeptors
EP1201660B1 (en) 2000-10-30 2005-08-31 Pfizer Products Inc. Glucocorticoid receptor modulators
US6462661B2 (en) * 2000-11-20 2002-10-08 Seagate Technology Llc RF ID tag attachment to a disc drive
MXPA03011935A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
CN1556708A (zh) 2001-08-31 2004-12-22 �Ƹ��� 抑制成年唐氏综合症患者认知退化的方法
CA2460144C (en) 2001-09-27 2010-11-02 Universite De Liege Pyridinic sulfonamide derivatives, method of production and use thereof
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
US8476254B2 (en) 2002-07-02 2013-07-02 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferson-α therapy
PT1521733E (pt) 2002-07-08 2014-10-29 Pfizer Prod Inc Moduladores do recetor de glucocorticoides
US8450379B2 (en) 2002-11-05 2013-05-28 Corcept Therapeutics, Inc. Methods for treating migraine
JP2006516651A (ja) 2003-02-04 2006-07-06 コーセプト セラピューティクス， インコーポレイテッド 産後精神病の処置のための抗糖質コルチコイド
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
US20050080061A1 (en) 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
ES2398239T3 (es) * 2003-11-10 2013-03-14 The Scripps Research Institute Composiciones y procedimientos para inducir la desdiferenciación celular
CA2545020A1 (en) * 2003-11-13 2005-05-26 Pfizer Products Inc. Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
TWI370129B (en) 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
JP2009535430A (ja) 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
MX2009008286A (es) * 2007-02-02 2009-08-12 Pfizer Prod Inc Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.
CN101616925B (zh) * 2007-02-02 2012-05-23 辉瑞产品公司 三环化合物及其作为糖皮质激素受体调节剂的用途

Also Published As

Publication number Publication date
TW200846325A (en) 2008-12-01
MY146087A (en) 2012-06-29
GT200900210A (es) 2010-04-05
CR10949A (es) 2009-08-07
GEP20125426B (en) 2012-03-26
MX2009008284A (es) 2009-08-12
PT2114970E (pt) 2011-09-22
EP2114970B1 (en) 2011-08-03
ZA200906060B (en) 2010-05-26
HN2008000179A (es) 2010-06-09
US20080312294A1 (en) 2008-12-18
JP4599462B2 (ja) 2010-12-15
WO2008093227A1 (en) 2008-08-07
MA31117B1 (fr) 2010-01-04
CU20090133A7 (es) 2011-10-31
UA95332C2 (uk) 2011-07-25
RS51646B (en) 2011-10-31
HK1135108A1 (en) 2010-05-28
CN101616896A (zh) 2009-12-30
IL199972A (en) 2013-09-30
BRPI0808634A2 (pt) 2014-08-05
AR065134A1 (es) 2009-05-20
NI200900149A (es) 2010-02-15
CL2008000329A1 (es) 2008-08-08
CR10948A (es) 2009-08-07
RS51970B (en) 2012-02-29
CL2008000330A1 (es) 2008-08-08
UA94639C2 (ru) 2011-05-25
TW200838514A (en) 2008-10-01
US20100286214A1 (en) 2010-11-11
CU23848B1 (es) 2012-10-15
SV2009003349A (es) 2010-04-13
NI200900148A (es) 2010-02-15
KR20090107080A (ko) 2009-10-12
US7786097B2 (en) 2010-08-31
AP2455A (en) 2012-08-31
ECSP099552A (es) 2009-08-28
US8445520B2 (en) 2013-05-21
KR101107949B1 (ko) 2012-02-08
MY153057A (en) 2014-12-31
CY1111758T1 (el) 2015-10-07
SI2114970T1 (sl) 2011-11-30
CA2676670A1 (en) 2008-08-07
US20140316139A1 (en) 2014-10-23
MY148780A (en) 2013-05-31
PE20081736A1 (es) 2008-11-28
US8158660B2 (en) 2012-04-17
US20120095062A1 (en) 2012-04-19
ATE518872T1 (de) 2011-08-15
SV2009003346A (es) 2010-04-13
CN101616896B (zh) 2012-07-04
DK2114970T3 (da) 2011-09-19
GT200900209A (es) 2010-07-22
ES2368286T3 (es) 2011-11-16
HN2008000178A (es) 2011-02-25
AP2009004942A0 (en) 2009-08-31
TN2009000324A1 (fr) 2010-12-31
US20080188443A1 (en) 2008-08-07
KR20090108115A (ko) 2009-10-14
PT2114888E (pt) 2011-01-04
ECSP099553A (es) 2009-08-28
KR101114682B1 (ko) 2012-03-14
TWI373466B (en) 2012-10-01
DOP2009000190A (es) 2009-08-31
US20140142316A1 (en) 2014-05-22
EP2114970A1 (en) 2009-11-11
CU20090132A7 (es) 2011-10-14
US7547714B2 (en) 2009-06-16
AU2008211613A1 (en) 2008-08-07
CN101616925A (zh) 2009-12-30
HRP20110702T1 (hr) 2011-10-31
GEP20125404B (en) 2012-02-27
US8901310B2 (en) 2014-12-02
EA200970666A1 (ru) 2010-02-26
AU2008211613B2 (en) 2013-05-23
CY1110962T1 (el) 2015-06-11
CO6220937A2 (es) 2010-11-19
US7598231B2 (en) 2009-10-06
AR065135A1 (es) 2009-05-20
CN101616925B (zh) 2012-05-23
ZA200906064B (en) 2010-05-26
TWI347842B (en) 2011-09-01
US20090281148A1 (en) 2009-11-12
EA016494B1 (ru) 2012-05-30
IL199972A0 (en) 2010-04-15
PL2114970T3 (pl) 2011-11-30
CU23824A3 (es) 2011-10-31
PE20090113A1 (es) 2009-02-13
NZ578638A (en) 2010-12-24
CA2676670C (en) 2012-03-13
ES2353822T3 (es) 2011-03-07
MA31158B1 (fr) 2010-02-01
US20120088802A9 (en) 2012-04-12
JP2010517990A (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
CO6190603A2 (es) Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide
CY1118189T1 (el) Εμπλουτισμος αφαλατωμενου και γλυκου νερου με χορηγηση ενος διαλυματος ανθρακικου ασβεστιου σε μαλακο νερο
CR20130004A (es) Derivados de tetrahidro-pirido-pirimidina
UY32045A (es) Compuesto amida
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
CL2012000181A1 (es) Composicion antimicrobiana para extender la vida util del agua, alimentos o ingredientes de alimentos que comprende 1% a 99% en peso de ácidos orgánicos en solucion acuosa, 0-20% de peso de terpenos y 0-5% de surfactantes; método para extender la vida util del agua, alimentos o ingredientes de alimentos.
BR112013029538A2 (pt) catalisador de reação de fenton produzido usando substância redutora orgânica como matéria-prima
EA201100896A1 (ru) Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение
CL2013002692A1 (es) Soluciones estabilizadas de acido hipohaloso y una cantidad estabilizadora de carbono inorganico disuelto; y metodo de preparacion de la misma.
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
UA113981C2 (xx) Офтальмологічний розчин, що містить диквафасол
EA201270216A1 (ru) Фармацевтический состав
EA201791850A1 (ru) Борсодержащие малые молекулы
AR089228A1 (es) Rendimiento dirigido de las composiciones de hipohalito, sus metodos y sistemas
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
AR065963A1 (es) Solucion acuosa de peroxido de hidrogeno, proceso para su preparacion y su uso
TW200633951A (en) Method for reducing cyclohexenone content of a cyclohexenone-containing organic mixture
TR201901635T4 (tr) Kıkırdak dokunun onarılmasına yönelik bileşim, bileşimin üretilmesine ve bunun kullanımına yönelik yöntem.
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
CR20110413A (es) Uso como bactericidas de análogos ácidos heteroaromáticos que contienen azufre
BR112013010918B8 (pt) composição compreendendo sal de cloridrato de alumínio, método de fabricação do referido sal e usos do mesmo
MX2011007952A (es) Tricianoboratos novedosos.
CO6362002A2 (es) Derivados de acido fenoxicroman carboxilico 6-sustituido
BR112014026483A2 (pt) composição antimicrobiana, composição antimicrobiana bicomponente, pano de limpeza, método para desinfetar uma superfície e método para controlar esporos sobre uma superfície
AR073807A1 (es) Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria.

Legal Events

Date Code Title Description
FG Application granted